Menu di pagina
- IRE Research and Technology
- IRE Competitive Grants
- PerfeTTO
- INNOVA
- Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)
- Artificial Intelligence and Machine Learning Based Risk Prediction Model for Improving Endometrial Cancer Clinical Management
- Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after robot-assisted surgical treatment of genitourinary cancers
- Deciphering KEAPness for Improved Immunotherapy Prediction and Treatment
- MiRNA-based therapeutic approach to fight triple negative breast cancer
- Beyond the creation of a living biobank: dissecting the transcriptomic landscape of Gastro-entero-pancreatic neuroendocrine neoplasms
- Multidimensional assessment of virus-associated head and neck cancer patients for the discovery of predictive biomarkers to guide clinical intervention
- TArgeting drug resistant melanoma with miCroRNAs delivered by Lipid NanoparTICles (TACTIC)
- Addressing liver fibrosis prevention and treatment: an unbiased query on the hepatic microenvironment with a perspective targeting of the pro-fibrotic kinase HIPK2
- Analyses of HPV and host body fluid biomarkers as non-invasive strategy for detection of head and neck cancer relapse
- Deciphering Biology of R/R DLBCL Subtypes: miRNA Biomarkers for Optimizing Treatment and Survival
- Clinically approved drugs targeting pyruvate kinase M2: a drug repurposing pathway to move forward the treatment of glioblastoma
- Developing a Biobank Network Among Major Sarcoma Treatment Centers to Improve Biomedical Research
- Identification and Validation of Prognostic and Predictive Biomarkers, Including E3 Ubiquitin Ligases and MicroRNA Signature, for the Development of New Immunotherapeutic Approaches in Glioma
- Heal Italia
- D3 4 Health
- TRIglIFO2 project
- Poc MIMIT Project
- The PROMlSE project
- The 4Immunogenomics project
- Project ERBB2
- Project NANO-COVID-TEST
- Progetto DOMINO – Lazio Innova
- Project GEMMA – Lazio Innova
- Project COMETA
- Exploring the role of Bcl-2 family in the immune surveillance of melanoma: from mechanisms to therapeutic perspectives
- Exploring how endothelin-1/PIEZO axis intersects mechanical forces to fuel PARP inhibitor resistance in ovarian cancer
- The PROGRESS Project
- ULYSSES Project
- VerSiLiB Project
- PRODIGI Project
- LASERBLOOD Project
- BioCIPN Project
BioCIPN Project

Full title: “A natural history of chemotherapy-induced peripheral neuropathies (BioCIPN)”
Web site of the Foundation ANTHEM: https://fondazioneanthem.it/
Project description

Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication associated with specific classes of drugs, and it can develop through diverse mechanisms and over varying timeframes. One challenge with CIPN concerns the ability to predict or stratify the risk of its occurrence, with a view to optimising individual cancer treatment.
Project start date: 11/09/2024
Project end date: 30/09/2026
Purpose
Through a multicentre observational study, BioCIPN project aims to conduct a longitudinal assessment of the natural history of peripheral neuropathies induced by some of the most commonly used anticancer drugs, with the aim of producing reproducible data on the actual incidence, severity, time to onset and neurophysiopathological profile. The project is being carried out in collaboration with the IRE Biobank (BBIRE)
and in partnership with the Fondazione Mondino IRCCS for the evaluation of circulating biomarkers as potential indicators of severity and prognosis, using state-of-the-art equipment purchased by Mondino.
The planned activities relate to two main work packages:
WP1 - Longitudinal clinical assessment of chemotherapy-induced peripheral neuropathies
WP2 - Assessment of biomarkers
IFO-IRE as Coordinator, is the leader and participates with its research activities within the WP1.
Contacts
Principal Investigator: Dr. Andrea Pace, Dr. Dario Benincasa: dario.benincasa@ifo.it
Results
During the project, validation of the NULISA platform was completed by Mondino Institute. Post-sequencing analyses were carried out on the first plate containing samples for instrument validation. An AQ inflammatory panel plate containing 86 samples (43 cerebrospinal fluid samples and 43 serum samples) from patients with inflammatory and neurodegenerative diseases was used. The analysis yielded satisfactory results, with an average sample detectability of 93.5 per cent. This experiment confirmed the platform’s high efficiency and the feasibility of proceeding with the study’s activities.
Over a third of the patients were recruited by IFO-IRE following an unforeseen screening failure; all data from these patients were collected in accordance with the clinical protocol, and the patients underwent the scheduled study procedures. NfL levels were measured in the collected samples using the NULISA platform, in cases of chemotherapy-associated neuropathies. The implementation of the Periferin assay and the biostatistical analysis will be completed by the participating institutions once recruitment of the full cohort and the necessary follow-up data have been finalised.
Financial Support
PNC, financed by Università degli Studi di Milano Bicocca.
Proposal submitted via PEC of 28/03/2024, approved with Determination n° 435/2024 protocol n. 0446501 of 26/09/2024.
The total grant of the project is 381.912,31 euro (CUP B53C22006670001)
The GRANT assigned to IFO-IRE is 118.831,41 euro.
The funding resources are from the public call “bando a cascata progetto ANTHEM: AdvaNced Technologies for Human-centrEd Medicine PNC0000003 – CUP B53C22006670001– Spoke 2 per attività di ricerca industriale e sviluppo sperimentale indirizzato a Organismi di Ricerca” Determination of Università degli Studi di Milano Bicocca n. 721/2024 prot. n. 0093950 of 19/02/2024, under the “Piano Nazionale per gli Investimenti Complementari (PNC) istituito con il decreto-legge 6 maggio 2021, n. 59 convertito dalla legge n. 101 del 2021), iniziative di ricerca per tecnologie e percorsi innovativi in ambito Sanitario e Assistenziale (Decreto Direttoriale n. 931 del 06-06-2022)”.




